Xintela AB Year-end Report 2025

Summary of the year-end reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2025Income amounted to TSEK 415 (1,090).Loss before tax totalled TSEK 17,343 (loss: 11,712).Loss per share was SEK 0.02 (loss: 0.02). Full year 2025Income amounted to TSEK 2,282 (4,215).Loss before tax totalled TSEK 50,158 (loss: 41,534).Loss per share […]

Xintela AB Year-end Report 2024

Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2024Income amounted to TSEK 1,090 (78).Loss before tax totalled TSEK 11,712 (loss: 12,175).Loss per share* was SEK 0.02 (loss: 0.03). Full year 2024Income amounted to TSEK 4,215 (78).Loss before tax totalled TSEK 41,534 (loss: 58,367).Loss […]

Xintela AB Year-end Report 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter 2023 for the groupIncome amounted to TSEK 78 (0).Loss before tax totalled TSEK 12,175 (loss: 23,384).Loss per share was SEK 0.03 (loss: 0.09). The year 2023 for the groupIncome amounted to TSEK 78 (0).Loss before and […]

Xintela Year-end report 2022

Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group Fourth quarter 2022 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 23,384 (loss: 18,013).Loss per share* was SEK 0.09 (loss: 0.20). Twelve months 2022 for the groupIncome […]

Xintela AB Year-end report January – December 2021

Summary of the year end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter October 1 – December 31, 2021Income amounted to TSEK 0 (0).Loss before tax totalled TSEK 26,643 (loss: 25,335).Loss per share* was SEK 0.30 (loss: 0.34).At December 31, 2021, the equity/assets ratio** was 16% (57). […]

Year-end report 1 Jan – 31 Dec 2020

Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Twelve months (1 Jan 2020-31 Dec 2020) Net sales amounted to TSEK 0 (38). Loss before tax totalled TSEK 50,257 (loss: 43,530). Loss per share* was SEK 0.68 (loss: 1.10). At 31 December 2020, the equity/assets ratio** […]

Year-end Report 2018

The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]

Year-end Report 2017

Strategic decisions, collaboration agreements and financing Xintela took major steps forward in 2017 and there is every reason to be optimistic about the new year. Our unique stem cell technology and the decision to establish our own GMP facility for stem cell production have made us a player to reckon with in regenerative medicine. We […]